{
     "PMID": "26361722",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20160920",
     "LR": "20161126",
     "IS": "1872-9754 (Electronic) 0197-0186 (Linking)",
     "VI": "90",
     "DP": "2015 Nov",
     "TI": "Neuroprotection by JM-20 against oxygen-glucose deprivation in rat hippocampal slices: Involvement of the Akt/GSK-3beta pathway.",
     "PG": "215-23",
     "LID": "10.1016/j.neuint.2015.09.003 [doi] S0197-0186(15)30045-0 [pii]",
     "AB": "Cerebral ischemia is the third most common cause of death and a major cause of disability worldwide. Beyond a shortage of essential metabolites, ischemia triggers many interconnected pathophysiological events, including excitotoxicity, oxidative stress, inflammation and apoptosis. Here, we investigated the neuroprotective mechanisms of JM-20, a novel synthetic molecule, focusing on the phosphoinositide-3-kinase (PI3K)/Akt survival pathway and glial cell response as potential targets of JM-20. For this purpose, we used organotypic hippocampal slice cultures exposed to oxygen-glucose deprivation (OGD) to achieve ischemic/reperfusion damage in vitro. Treatment with JM-20 at 0.1 and 10 muM reduced PI incorporation (indicative of cell death) after OGD. OGD decreased the phosphorylation of Akt (pro-survival) and GSK 3beta (pro-apoptotic), resulting in respective inhibition and activation of these proteins. Treatment with JM20 prevented the reduced phosphorylation of these proteins after OGD, representing a shift from pro-apoptotic to pro-survival signaling. The OGD-induced activation of caspase-3 was also attenuated by JM-20 treatment at 10 muM. Moreover, in cultures treated with JM-20 and exposed to OGD conditioning, we observed a decrease in activated microglia, as well as a decrease in interleukin (IL)-1beta, IL-6 and tumor necrosis factor (TNF)-alpha release into the culture medium, while the level of the anti-inflammatory IL-10 increased. GFAP immunostaining and IB4 labeling showed that JM-20 treatment significantly augmented GFAP immunoreactivity after OGD, when compared with cultures exposed to OGD only, suggesting the activation of astroglial cells. Our results confirm that JM-20 has a strong neuroprotective effect against ischemic injury and suggest that the mechanisms involved in this effect may include the modulation of reactive astrogliosis, as well as neuroinflammation and the anti-apoptotic cell signaling pathway.",
     "CI": [
          "Copyright (c) 2015 Elsevier Ltd. All rights reserved."
     ],
     "FAU": [
          "Ramirez-Sanchez, Jeney",
          "Simoes Pires, Elisa Nicoloso",
          "Nunez-Figueredo, Yanier",
          "Pardo-Andreu, Gilberto L",
          "Fonseca-Fonseca, Luis Arturo",
          "Ruiz-Reyes, Alberto",
          "Ochoa-Rodriguez, Estael",
          "Verdecia-Reyes, Yamila",
          "Delgado-Hernandez, Rene",
          "Souza, Diogo O",
          "Salbego, Christianne"
     ],
     "AU": [
          "Ramirez-Sanchez J",
          "Simoes Pires EN",
          "Nunez-Figueredo Y",
          "Pardo-Andreu GL",
          "Fonseca-Fonseca LA",
          "Ruiz-Reyes A",
          "Ochoa-Rodriguez E",
          "Verdecia-Reyes Y",
          "Delgado-Hernandez R",
          "Souza DO",
          "Salbego C"
     ],
     "AD": "Centro de Investigacion y Desarrollo de Medicamentos, Ave 26, No. 1605 Boyeros y Puentes Grandes, CP 10600 La Habana, Cuba. Programa de Pos-graduacao em Bioquimica, Departamento de Bioquimica, ICBS, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600-Anexo I, Porto Alegre, RS 90035-003, Brazil. Centro de Investigacion y Desarrollo de Medicamentos, Ave 26, No. 1605 Boyeros y Puentes Grandes, CP 10600 La Habana, Cuba. Centro de Estudio para las Investigaciones y Evaluaciones Biologicas, Instituto de Farmacia y Alimentos, Universidad de La Habana, ave. 23 # 21425 e/214 y 222, La Coronela, La Lisa CP 13600, La Habana, Cuba. Centro de Investigacion y Desarrollo de Medicamentos, Ave 26, No. 1605 Boyeros y Puentes Grandes, CP 10600 La Habana, Cuba. Laboratorio de Sintesis Organica de La Facultad de Quimica de La Universidad de La Habana, Zapata s/n entre G y Carlitos Aguirre, Vedado Plaza de la Revolucion, CP 10400, La Habana, Cuba. Laboratorio de Sintesis Organica de La Facultad de Quimica de La Universidad de La Habana, Zapata s/n entre G y Carlitos Aguirre, Vedado Plaza de la Revolucion, CP 10400, La Habana, Cuba. Laboratorio de Sintesis Organica de La Facultad de Quimica de La Universidad de La Habana, Zapata s/n entre G y Carlitos Aguirre, Vedado Plaza de la Revolucion, CP 10400, La Habana, Cuba. Centro de Investigacion y Desarrollo de Medicamentos, Ave 26, No. 1605 Boyeros y Puentes Grandes, CP 10600 La Habana, Cuba. Programa de Pos-graduacao em Bioquimica, Departamento de Bioquimica, ICBS, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600-Anexo I, Porto Alegre, RS 90035-003, Brazil; Departamento de Bioquimica, PPG em Bioquimica, PPG em Educacao em Ciencia, Instituto de Ciencias Basicas da Saude, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600 anexo, Porto Alegre, RS 90035-003, Brazil. Programa de Pos-graduacao em Bioquimica, Departamento de Bioquimica, ICBS, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600-Anexo I, Porto Alegre, RS 90035-003, Brazil; Departamento de Bioquimica, PPG em Bioquimica, PPG em Educacao em Ciencia, Instituto de Ciencias Basicas da Saude, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2600 anexo, Porto Alegre, RS 90035-003, Brazil. Electronic address: 00007090@ufrgs.br.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20150908",
     "PL": "England",
     "TA": "Neurochem Int",
     "JT": "Neurochemistry international",
     "JID": "8006959",
     "RN": [
          "0",
          "(3-ethoxycarbonyl-2-methyl-4-(2-nitrophenyl)-4,11-dihydro-1H-pyrido(2,3-b)(1,5)be",
          "nzodiazepine)",
          "0 (Neuroprotective Agents)",
          "12794-10-4 (Benzodiazepines)",
          "2679MF687A (Niacin)",
          "EC 2.7.1.- (Phosphatidylinositol 3-Kinases)",
          "EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta)",
          "EC 2.7.11.1 (Gsk3b protein, rat)",
          "EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)",
          "EC 2.7.11.26 (Glycogen Synthase Kinase 3)",
          "IY9XDZ35W2 (Glucose)",
          "S88TT14065 (Oxygen)"
     ],
     "SB": "IM",
     "MH": [
          "Animals",
          "Animals, Newborn",
          "Benzodiazepines/*pharmacology",
          "Cell Death/*drug effects",
          "Glucose/metabolism",
          "Glycogen Synthase Kinase 3/*metabolism",
          "Glycogen Synthase Kinase 3 beta",
          "Hippocampus/*drug effects/metabolism",
          "Male",
          "Neurons/drug effects",
          "Neuroprotection/drug effects",
          "Neuroprotective Agents/pharmacology",
          "Niacin/*analogs & derivatives/pharmacology",
          "Oxygen/*metabolism",
          "Phosphatidylinositol 3-Kinases/metabolism",
          "Proto-Oncogene Proteins c-akt/*metabolism",
          "Rats, Wistar"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "Akt",
          "GSK-3beta",
          "JM-20",
          "Neuroinflammation",
          "Neuroprotection",
          "Oxygen-glucose deprivation"
     ],
     "EDAT": "2015/09/13 06:00",
     "MHDA": "2016/09/22 06:00",
     "CRDT": [
          "2015/09/13 06:00"
     ],
     "PHST": [
          "2015/04/15 00:00 [received]",
          "2015/09/03 00:00 [revised]",
          "2015/09/04 00:00 [accepted]",
          "2015/09/13 06:00 [entrez]",
          "2015/09/13 06:00 [pubmed]",
          "2016/09/22 06:00 [medline]"
     ],
     "AID": [
          "S0197-0186(15)30045-0 [pii]",
          "10.1016/j.neuint.2015.09.003 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Neurochem Int. 2015 Nov;90:215-23. doi: 10.1016/j.neuint.2015.09.003. Epub 2015 Sep 8.",
     "term": "hippocampus"
}